Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models-Reference-Cited by-同舟云学术

Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models

Published:2021-03-24 Issue:586 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Schneider Dina¹^ORCID,Xiong Ying¹^ORCID,Wu Darong¹,Hu Peirong¹,Alabanza Leah¹,Steimle Brittany¹^ORCID,Mahmud Hasan¹,Anthony-Gonda Kim¹^ORCID,Krueger Winfried¹^ORCID,Zhu Zhongyu¹^ORCID,Dimitrov Dimiter S.¹^ORCID,Orentas Rimas J.¹^ORCID,Dropulić Boro¹^ORCID

Affiliation:

1. Lentigen, a Miltenyi Biotec Company, Gaithersburg, MD 20878, USA.

Abstract

Trispecific duoCAR-T cells with optimized costimulatory domains effectively kill tumor cells in antigen-heterogeneous and antigen-replete tumor models.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference51 articles.

1. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

2. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

3. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

4. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

5. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies;Blood Reviews;2024-09

2. CD28 hinge used in chimeric antigen receptor (CAR) T-cells exhibits local structure and conformational exchange amidst global disorder;Communications Biology;2024-08-31

3. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy;Journal of Translational Medicine;2024-08-05

4. Effectors of the Future: Universal Chimeric Antigen Receptor;Transfusion Medicine and Hemotherapy;2024-07-15

5. Universal CAR 2.0 to overcome current limitations in CAR therapy;Frontiers in Immunology;2024-06-19